Of note, VS-6063 in combination with pembrolizumab for advanced pancreatic cancer is in Phase II clinical trials (NCT03727880), the purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody, and is expected to complete in August, 2022 [90]. The gene discussed is PTK2; the disease is neoplasm.